Sun Pharmaceutical Industries Ltd., of Mumbai, India, and subsidiary Sun Pharma Advanced Research Co. Ltd. (SPARC), of Princeton, N.J., received FDA approval for Xelpros (latanoprost ophthalmic emulsion), triggering an undisclosed milestone payment to SPARC under the firms' 2015 deal. SPARC also is eligible for milestones and royalties on commercialization of Xelpros in the U.S.